Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

2024.09.09
A large population-based cohort study led by Dr. Mollie E. Barnard from the Huntsman Cancer Institute at the University of Utah has found that women with endometriosis have an overall higher risk of ovarian cancer, with the risk being significantly elevated in those with severe types of endometriosis. This study, published in the journal of the American Medical Association [1], suggests that these women may benefit from counseling on ovarian cancer risk and prevention, as well as potential ovarian cancer screening.
Lung Cancer Guidelines: ASCO Updates Stage III NSCLC Guidelines Based on LAURA Trial Data, Including Osimertinib

Lung Cancer Guidelines: ASCO Updates Stage III NSCLC Guidelines Based on LAURA Trial Data, Including Osimertinib

2024.09.09
The Phase 3 Non-Small Cell Lung Cancer (NSCLC) Treatment ASCO Guidelines has recently been updated, with the revisions based on the results of the Phase 3 LAURA trial. The findings were presented at the 2024 ASCO Annual Meeting and published simultaneously in the New England Journal of Medicine [1, 2]. The new guidelines include a recommendation to use the EGFR-TKI osimertinib in patients with unresectable Stage III NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations after definitive chemoradiotherapy (CRT).
Mutual Learning Between China and Germany丨International Perspectives, Leading the Frontier: The Academic Journey of Dr. Jürgen Wolf from the Universit

Mutual Learning Between China and Germany丨International Perspectives, Leading the Frontier: The Academic Journey of Dr. Jürgen Wolf from the Universit

2024.09.08
With an international perspective and a focus on leading-edge advancements, the Overseas Experts China Tour project welcomed a prominent figure in the field of lung cancer from August 5th to 10th, 2024—Dr. Jürgen Wolf, Director of the Centre for Integrated Oncology (CIO) at University Hospital of Cologne, Professor of Interdisciplinary Translational Oncology at the University of Cologne, and Head of the CIO Lung Cancer Program. During his five-day academic exchange tour in China, Professor Wolf visited Chengdu, Hangzhou, Changsha, and Qingdao, attracting lung cancer experts from across the country for discussions and exchanges. Throughout these academic activities, Professor Wolf not only shared the experiences of lung cancer diagnosis and treatment in Germany but also engaged in vigorous academic discussions with Chinese experts on the latest advancements and contentious topics in lung cancer treatment, sparking many brilliant ideas.
Dr. Zhizhong Pan: The Journey of Colorectal Cancer Immunotherapy Research—Experiences from Sun Yat-sen University Cancer Center丨Guangzhou Colorectal Cancer Summit Forum

Dr. Zhizhong Pan: The Journey of Colorectal Cancer Immunotherapy Research—Experiences from Sun Yat-sen University Cancer Center丨Guangzhou Colorectal Cancer Summit Forum

2024.09.08
At the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Colorectal Cancer Academic Conference held from August 5-10, 2024, Dr. Zhizhong Pan from Sun Yat-sen University Cancer Center delivered an insightful presentation titled "The Journey of Colorectal Cancer Immunotherapy Research: Experiences from Sun Yat-sen University Cancer Center." After the conference, Professor Pan granted us an interview, and we have compiled the content below for our readers.
Insights from Hematology Expert | Dr. Jianxiang Wang: Delving into Immune Mechanisms to Pioneer New Target Frontiers

Insights from Hematology Expert | Dr. Jianxiang Wang: Delving into Immune Mechanisms to Pioneer New Target Frontiers

2024.09.05
The breakthrough achievements of CAR-T therapy in the field of hematologic malignancies are remarkable. However, challenges such as target limitations, limited cell sources, and durability of efficacy continue to necessitate further exploration. Dr. Jianxiang Wang's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , stands as a pioneer in the field of immunotherapy, advancing both basic and clinical research to push the boundaries of hematologic cancer immunotherapy. In this issue of Hematology Frontier, Dr. Jianxiang Wang shares the research outcomes and forward-looking insights of his team in the realm of immunotherapy. The aim is to inspire new clinical thinking and collaboratively open a new chapter in hematologic cancer immunotherapy, bringing more hope and possibilities to patients.
Dr. Ruiyun Zhang: New Approaches Like Targeted Immunotherapy and ctDNA Further Address the Bladder-Preserving Needs of MIBC Patients | 2024 ASCOBT

Dr. Ruiyun Zhang: New Approaches Like Targeted Immunotherapy and ctDNA Further Address the Bladder-Preserving Needs of MIBC Patients | 2024 ASCOBT

2024.09.05
The ASCO Breakthrough Summit, held from August 8th to 10th in Yokohama, Japan, focused on new technologies in cancer treatment and shared breakthrough advances and research that are driving global cancer treatment forward. The research titled "Preliminary results of an open-label, single-arm, multi-center study on disitamab vedotin (DV) combined with toripalimab and radiotherapy as bladder-preserving therapy in HER2 overexpression muscle-invasive bladder cancer (MIBC; DECIDING study-stage I)" by Dr. Haige Chen and Dr. Ruiyun Zhang from Renji Hospital, Shanghai JiaoTong University School of Medicine, was selected for presentation. Urology Frontier invited Dr. Ruiyun Zhang to discuss the treatment needs of MIBC patients, the DECIDING study results, progress in ctDNA, and the team's ongoing explorations.